| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 248 | 2023 | 5181 | 17.480 |
Why?
|
| Diphosphonates | 25 | 2022 | 623 | 4.300 |
Why?
|
| Bone Diseases | 13 | 2021 | 416 | 3.890 |
Why?
|
| Bone Density Conservation Agents | 20 | 2022 | 772 | 3.440 |
Why?
|
| Imidazoles | 15 | 2018 | 1206 | 2.500 |
Why?
|
| Thalidomide | 31 | 2021 | 890 | 2.230 |
Why?
|
| Immunotherapy, Adoptive | 16 | 2023 | 1271 | 2.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 61 | 2023 | 11525 | 2.200 |
Why?
|
| Antineoplastic Agents | 61 | 2022 | 13693 | 1.940 |
Why?
|
| B-Cell Maturation Antigen | 10 | 2023 | 140 | 1.830 |
Why?
|
| Osteoclasts | 18 | 2020 | 729 | 1.710 |
Why?
|
| Dexamethasone | 40 | 2023 | 1951 | 1.630 |
Why?
|
| Cyclin-Dependent Kinases | 5 | 2015 | 671 | 1.560 |
Why?
|
| Osteolysis | 6 | 2017 | 270 | 1.510 |
Why?
|
| Oligopeptides | 14 | 2021 | 1189 | 1.480 |
Why?
|
| Osteoblasts | 11 | 2017 | 1166 | 1.390 |
Why?
|
| Boronic Acids | 31 | 2015 | 965 | 1.300 |
Why?
|
| Bone Neoplasms | 9 | 2022 | 2530 | 1.270 |
Why?
|
| Bone Remodeling | 7 | 2018 | 575 | 1.250 |
Why?
|
| Hydroxamic Acids | 6 | 2017 | 494 | 1.220 |
Why?
|
| Pyrazines | 31 | 2015 | 1230 | 1.170 |
Why?
|
| Osteonecrosis | 8 | 2014 | 227 | 1.120 |
Why?
|
| RANK Ligand | 5 | 2018 | 326 | 1.110 |
Why?
|
| Apoptosis | 45 | 2016 | 9724 | 1.040 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 177 | 1.030 |
Why?
|
| Agammaglobulinemia | 2 | 2023 | 167 | 1.030 |
Why?
|
| Plasmacytoma | 6 | 2015 | 183 | 1.010 |
Why?
|
| Mice, SCID | 26 | 2022 | 2716 | 0.990 |
Why?
|
| Bone Resorption | 8 | 2022 | 723 | 0.980 |
Why?
|
| Antibodies, Monoclonal | 15 | 2023 | 9274 | 0.950 |
Why?
|
| Spinal Cord Compression | 4 | 2023 | 235 | 0.940 |
Why?
|
| Antibodies, Bispecific | 2 | 2023 | 164 | 0.930 |
Why?
|
| Histone Deacetylase Inhibitors | 8 | 2021 | 789 | 0.910 |
Why?
|
| Bone Diseases, Metabolic | 4 | 2017 | 417 | 0.890 |
Why?
|
| B-Cell Activating Factor | 4 | 2016 | 119 | 0.880 |
Why?
|
| Neutropenia | 5 | 2023 | 895 | 0.840 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2022 | 31 | 0.840 |
Why?
|
| Pyrimidines | 8 | 2018 | 2943 | 0.830 |
Why?
|
| Cell Line, Tumor | 50 | 2021 | 16690 | 0.820 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2021 | 32 | 0.820 |
Why?
|
| Drug Resistance, Neoplasm | 23 | 2021 | 5172 | 0.810 |
Why?
|
| Bone and Bones | 7 | 2020 | 2576 | 0.810 |
Why?
|
| Humans | 285 | 2024 | 744366 | 0.800 |
Why?
|
| Fractures, Spontaneous | 3 | 2018 | 230 | 0.760 |
Why?
|
| Bone Marrow | 15 | 2016 | 2948 | 0.760 |
Why?
|
| Hypercalcemia | 3 | 2022 | 409 | 0.760 |
Why?
|
| Lipolysis | 1 | 2022 | 210 | 0.760 |
Why?
|
| Bone Marrow Cells | 23 | 2011 | 2513 | 0.750 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2017 | 1677 | 0.730 |
Why?
|
| Activins | 2 | 2013 | 208 | 0.730 |
Why?
|
| Urea | 2 | 2013 | 450 | 0.710 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 648 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2019 | 1434 | 0.710 |
Why?
|
| Neoplasm Proteins | 11 | 2016 | 3707 | 0.690 |
Why?
|
| Sulfonamides | 4 | 2019 | 1940 | 0.680 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 19 | 2022 | 5445 | 0.670 |
Why?
|
| Macrocyclic Compounds | 1 | 2019 | 72 | 0.670 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2018 | 79 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 988 | 0.640 |
Why?
|
| Tumor Microenvironment | 6 | 2019 | 3590 | 0.640 |
Why?
|
| Neoplasm, Residual | 4 | 2023 | 973 | 0.630 |
Why?
|
| Drug Synergism | 16 | 2015 | 1794 | 0.630 |
Why?
|
| Tumor Cells, Cultured | 33 | 2022 | 6313 | 0.620 |
Why?
|
| Cancer Vaccines | 4 | 2018 | 1023 | 0.600 |
Why?
|
| Cell Cycle | 11 | 2016 | 2967 | 0.580 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2021 | 2043 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2023 | 9240 | 0.540 |
Why?
|
| Melphalan | 12 | 2022 | 431 | 0.520 |
Why?
|
| Decorin | 1 | 2015 | 40 | 0.520 |
Why?
|
| Isoxazoles | 1 | 2016 | 216 | 0.520 |
Why?
|
| Stromal Cells | 19 | 2013 | 1355 | 0.510 |
Why?
|
| Phosphorylcholine | 4 | 2011 | 162 | 0.510 |
Why?
|
| Transplantation, Autologous | 15 | 2022 | 2124 | 0.510 |
Why?
|
| Adipocytes | 1 | 2022 | 1185 | 0.500 |
Why?
|
| Pyrazoles | 4 | 2018 | 1972 | 0.500 |
Why?
|
| Waldenstrom Macroglobulinemia | 7 | 2021 | 1052 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 16 | 2014 | 3554 | 0.490 |
Why?
|
| Benzazepines | 1 | 2016 | 326 | 0.490 |
Why?
|
| Medical Oncology | 7 | 2022 | 2267 | 0.470 |
Why?
|
| Biological Products | 2 | 2022 | 860 | 0.470 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 2725 | 0.470 |
Why?
|
| Fatty Acids | 1 | 2022 | 1809 | 0.470 |
Why?
|
| Lymphoma | 1 | 2022 | 1877 | 0.460 |
Why?
|
| Mesenchymal Stem Cells | 5 | 2017 | 1632 | 0.450 |
Why?
|
| Antibodies, Neutralizing | 3 | 2013 | 1978 | 0.450 |
Why?
|
| Chemokine CCL3 | 4 | 2011 | 84 | 0.450 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2021 | 5534 | 0.450 |
Why?
|
| Stem Cell Transplantation | 6 | 2023 | 1620 | 0.440 |
Why?
|
| DNA Damage | 5 | 2016 | 2432 | 0.440 |
Why?
|
| Sirolimus | 3 | 2014 | 1565 | 0.430 |
Why?
|
| Amyloidosis | 3 | 2012 | 796 | 0.420 |
Why?
|
| Mice | 48 | 2022 | 81201 | 0.420 |
Why?
|
| Acrylamides | 1 | 2014 | 255 | 0.420 |
Why?
|
| Cell Proliferation | 29 | 2018 | 10483 | 0.400 |
Why?
|
| Herpesvirus 8, Human | 5 | 2002 | 258 | 0.400 |
Why?
|
| Spinal Fractures | 4 | 2023 | 696 | 0.390 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2013 | 2038 | 0.390 |
Why?
|
| Morpholines | 1 | 2014 | 571 | 0.390 |
Why?
|
| Cell Survival | 15 | 2016 | 5882 | 0.390 |
Why?
|
| Down-Regulation | 12 | 2011 | 3001 | 0.390 |
Why?
|
| Hematology | 1 | 2014 | 221 | 0.390 |
Why?
|
| Caspases | 11 | 2010 | 928 | 0.380 |
Why?
|
| Boron Compounds | 4 | 2018 | 178 | 0.380 |
Why?
|
| Aged | 62 | 2021 | 163288 | 0.380 |
Why?
|
| Jaw Diseases | 2 | 2008 | 90 | 0.380 |
Why?
|
| Adjuvants, Immunologic | 3 | 2006 | 1000 | 0.370 |
Why?
|
| Male | 84 | 2023 | 350115 | 0.370 |
Why?
|
| Neoplasms | 12 | 2024 | 21696 | 0.370 |
Why?
|
| Interleukin-6 | 23 | 2015 | 3203 | 0.370 |
Why?
|
| Consensus | 5 | 2023 | 2960 | 0.370 |
Why?
|
| Calcification, Physiologic | 1 | 2011 | 169 | 0.370 |
Why?
|
| Osteocalcin | 1 | 2011 | 273 | 0.370 |
Why?
|
| Disease-Free Survival | 18 | 2022 | 6896 | 0.370 |
Why?
|
| Salvage Therapy | 7 | 2021 | 1275 | 0.360 |
Why?
|
| Fractures, Compression | 2 | 2023 | 133 | 0.350 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2014 | 2110 | 0.350 |
Why?
|
| Treatment Outcome | 36 | 2023 | 63107 | 0.350 |
Why?
|
| Enzyme Activation | 12 | 2016 | 3702 | 0.350 |
Why?
|
| Education, Medical, Continuing | 2 | 2014 | 840 | 0.340 |
Why?
|
| Female | 82 | 2023 | 380193 | 0.340 |
Why?
|
| Flavones | 1 | 2009 | 66 | 0.330 |
Why?
|
| Piperidines | 3 | 2021 | 1602 | 0.330 |
Why?
|
| Animals | 52 | 2022 | 168768 | 0.330 |
Why?
|
| T-Lymphocytes | 12 | 2023 | 10183 | 0.330 |
Why?
|
| Glycine | 4 | 2018 | 671 | 0.330 |
Why?
|
| Immunotherapy | 7 | 2021 | 4446 | 0.330 |
Why?
|
| Indoles | 2 | 2015 | 1839 | 0.320 |
Why?
|
| Middle Aged | 58 | 2021 | 213390 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 10 | 2021 | 7282 | 0.320 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 728 | 0.320 |
Why?
|
| Benzimidazoles | 2 | 2011 | 850 | 0.320 |
Why?
|
| Anemia | 2 | 2023 | 1503 | 0.310 |
Why?
|
| Signal Transduction | 22 | 2018 | 23404 | 0.310 |
Why?
|
| Protease Inhibitors | 8 | 2014 | 791 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2021 | 8432 | 0.310 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2012 | 1524 | 0.310 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 430 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2014 | 2504 | 0.310 |
Why?
|
| Glycoproteins | 1 | 2016 | 2266 | 0.310 |
Why?
|
| Cyclin D1 | 2 | 2009 | 463 | 0.300 |
Why?
|
| Plasma Cells | 3 | 2019 | 591 | 0.300 |
Why?
|
| Coculture Techniques | 8 | 2022 | 1341 | 0.290 |
Why?
|
| Osteogenesis | 3 | 2011 | 1299 | 0.290 |
Why?
|
| Drug Resistance, Multiple | 3 | 2021 | 252 | 0.290 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 57776 | 0.290 |
Why?
|
| Dendritic Cells | 5 | 2013 | 2725 | 0.280 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 7721 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2013 | 2949 | 0.280 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2014 | 2455 | 0.280 |
Why?
|
| Purines | 2 | 2010 | 594 | 0.270 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 550 | 0.260 |
Why?
|
| Disease Management | 5 | 2021 | 2460 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2016 | 4554 | 0.260 |
Why?
|
| Paraproteinemias | 3 | 2019 | 246 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2020 | 10943 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 6539 | 0.250 |
Why?
|
| Interferon Regulatory Factors | 2 | 2016 | 270 | 0.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3595 | 0.240 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2021 | 627 | 0.240 |
Why?
|
| Drug Administration Schedule | 6 | 2021 | 4933 | 0.240 |
Why?
|
| STAT3 Transcription Factor | 4 | 2016 | 874 | 0.240 |
Why?
|
| Adult | 45 | 2023 | 214052 | 0.230 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2023 | 36 | 0.230 |
Why?
|
| Mutation | 7 | 2021 | 29786 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2014 | 3773 | 0.220 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 5856 | 0.220 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 2916 | 0.220 |
Why?
|
| History, 21st Century | 2 | 2020 | 1534 | 0.220 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 11031 | 0.220 |
Why?
|
| Neoplasm Transplantation | 5 | 2016 | 2086 | 0.220 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 1832 | 0.220 |
Why?
|
| Osteoporosis | 1 | 2012 | 1579 | 0.220 |
Why?
|
| Bone Marrow Transplantation | 9 | 2001 | 2765 | 0.210 |
Why?
|
| Osteocytes | 2 | 2017 | 197 | 0.210 |
Why?
|
| Cell Adhesion | 12 | 2016 | 3144 | 0.210 |
Why?
|
| Cell Lineage | 2 | 2021 | 2504 | 0.210 |
Why?
|
| Recurrence | 13 | 2021 | 8340 | 0.210 |
Why?
|
| Phosphorylation | 14 | 2013 | 8436 | 0.210 |
Why?
|
| Hip Fractures | 1 | 2010 | 955 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2000 | 1520 | 0.210 |
Why?
|
| Collagen Type I | 2 | 2015 | 592 | 0.200 |
Why?
|
| Clinical Trials as Topic | 9 | 2017 | 7914 | 0.200 |
Why?
|
| Splenomegaly | 1 | 2002 | 190 | 0.200 |
Why?
|
| Blotting, Western | 9 | 2012 | 5181 | 0.190 |
Why?
|
| Immunologic Factors | 8 | 2014 | 1580 | 0.190 |
Why?
|
| Kyphoplasty | 2 | 2019 | 44 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 11 | 2010 | 2016 | 0.190 |
Why?
|
| Combined Modality Therapy | 13 | 2018 | 8642 | 0.190 |
Why?
|
| Receptors, CCR1 | 2 | 2011 | 33 | 0.180 |
Why?
|
| Transcription Factors | 4 | 2016 | 12207 | 0.180 |
Why?
|
| Doxorubicin | 8 | 2018 | 2234 | 0.180 |
Why?
|
| Spinal Injuries | 1 | 2023 | 301 | 0.180 |
Why?
|
| Antibodies | 2 | 2007 | 2460 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 11726 | 0.170 |
Why?
|
| Osteoprotegerin | 2 | 2018 | 176 | 0.170 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 112 | 0.170 |
Why?
|
| Receptors, CXCR4 | 2 | 2021 | 727 | 0.170 |
Why?
|
| Drug Administration Routes | 2 | 2021 | 153 | 0.170 |
Why?
|
| Phosphoramide Mustards | 1 | 2018 | 16 | 0.170 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 290 | 0.170 |
Why?
|
| Nitrogen | 1 | 2020 | 344 | 0.170 |
Why?
|
| Palliative Care | 1 | 2014 | 3493 | 0.170 |
Why?
|
| Flow Cytometry | 8 | 2021 | 5974 | 0.170 |
Why?
|
| Adenine | 2 | 2021 | 936 | 0.160 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 808 | 0.160 |
Why?
|
| Infusions, Intravenous | 3 | 2019 | 2274 | 0.160 |
Why?
|
| I-kappa B Kinase | 3 | 2009 | 252 | 0.160 |
Why?
|
| Erdheim-Chester Disease | 1 | 2018 | 11 | 0.160 |
Why?
|
| Proteasome Endopeptidase Complex | 5 | 2011 | 1335 | 0.160 |
Why?
|
| Remission Induction | 9 | 2023 | 2385 | 0.160 |
Why?
|
| Immunoconjugates | 2 | 2020 | 901 | 0.160 |
Why?
|
| MicroRNAs | 1 | 2014 | 3751 | 0.160 |
Why?
|
| Etodolac | 3 | 2007 | 20 | 0.160 |
Why?
|
| Nitroimidazoles | 1 | 2018 | 106 | 0.150 |
Why?
|
| Sodium Fluoride | 1 | 2017 | 65 | 0.150 |
Why?
|
| Cell Line | 7 | 2022 | 16000 | 0.150 |
Why?
|
| Asymptomatic Diseases | 3 | 2017 | 551 | 0.150 |
Why?
|
| Protein Kinases | 1 | 2004 | 1640 | 0.150 |
Why?
|
| Bone Cements | 1 | 2019 | 325 | 0.150 |
Why?
|
| Cell Division | 11 | 2007 | 4569 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 625 | 0.150 |
Why?
|
| DNA Repair | 1 | 2006 | 2046 | 0.150 |
Why?
|
| Gene Expression Profiling | 7 | 2016 | 9445 | 0.150 |
Why?
|
| Antigens, CD19 | 1 | 2019 | 380 | 0.140 |
Why?
|
| Prednisolone | 3 | 2009 | 334 | 0.140 |
Why?
|
| Administration, Oral | 4 | 2018 | 3914 | 0.140 |
Why?
|
| Prognosis | 13 | 2023 | 29060 | 0.140 |
Why?
|
| Leukemic Infiltration | 1 | 1996 | 48 | 0.140 |
Why?
|
| Up-Regulation | 5 | 2021 | 4222 | 0.140 |
Why?
|
| Whole Body Imaging | 1 | 2018 | 280 | 0.140 |
Why?
|
| Medicine, Traditional | 1 | 1996 | 91 | 0.140 |
Why?
|
| Cranial Irradiation | 2 | 1996 | 401 | 0.140 |
Why?
|
| Enzyme Inhibitors | 8 | 2010 | 3799 | 0.140 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 760 | 0.140 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 171 | 0.140 |
Why?
|
| NF-kappa B | 6 | 2011 | 2499 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 961 | 0.140 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 711 | 0.140 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 1879 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2018 | 1821 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2010 | 1375 | 0.130 |
Why?
|
| Ikaros Transcription Factor | 1 | 2016 | 217 | 0.130 |
Why?
|
| Histiocytosis | 1 | 2015 | 40 | 0.130 |
Why?
|
| Clodronic Acid | 2 | 2013 | 60 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2019 | 629 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 15520 | 0.130 |
Why?
|
| Alendronate | 2 | 2020 | 171 | 0.130 |
Why?
|
| Quality of Life | 5 | 2023 | 12802 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2008 | 697 | 0.130 |
Why?
|
| Survival Analysis | 8 | 2018 | 10252 | 0.130 |
Why?
|
| Peptides | 3 | 2018 | 4410 | 0.120 |
Why?
|
| Autophagy | 2 | 2015 | 1297 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1656 | 0.120 |
Why?
|
| Cell Differentiation | 8 | 2014 | 11486 | 0.120 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2016 | 182 | 0.120 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2018 | 880 | 0.120 |
Why?
|
| Phagosomes | 1 | 2015 | 193 | 0.120 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 3508 | 0.120 |
Why?
|
| Models, Economic | 1 | 2018 | 712 | 0.120 |
Why?
|
| Immunophenotyping | 5 | 2012 | 1880 | 0.110 |
Why?
|
| Transplantation, Heterologous | 7 | 2010 | 2383 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 713 | 0.110 |
Why?
|
| RNA, Transfer | 1 | 2016 | 316 | 0.110 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 112 | 0.110 |
Why?
|
| Immunosuppressive Agents | 3 | 2005 | 4153 | 0.110 |
Why?
|
| Double-Blind Method | 2 | 2018 | 12025 | 0.110 |
Why?
|
| Syndecan-1 | 2 | 2015 | 165 | 0.110 |
Why?
|
| Anilides | 1 | 2016 | 408 | 0.110 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 733 | 0.110 |
Why?
|
| Ritonavir | 1 | 2014 | 322 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 504 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2012 | 2505 | 0.110 |
Why?
|
| beta Catenin | 2 | 2009 | 1059 | 0.110 |
Why?
|
| Piperazines | 5 | 2011 | 2488 | 0.110 |
Why?
|
| Retreatment | 3 | 2020 | 610 | 0.110 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 931 | 0.110 |
Why?
|
| Cytokines | 6 | 2014 | 7323 | 0.110 |
Why?
|
| Single-Cell Analysis | 3 | 2021 | 2182 | 0.110 |
Why?
|
| Cell Communication | 3 | 2009 | 1621 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1996 | 640 | 0.110 |
Why?
|
| Vaccination | 2 | 2023 | 3279 | 0.110 |
Why?
|
| Retrospective Studies | 10 | 2023 | 77460 | 0.110 |
Why?
|
| Methotrexate | 2 | 1996 | 1728 | 0.110 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2010 | 452 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2010 | 323 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2010 | 730 | 0.100 |
Why?
|
| Positron-Emission Tomography | 4 | 2022 | 6234 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 1683 | 0.100 |
Why?
|
| Biphenyl Compounds | 2 | 2006 | 913 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2007 | 1284 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 3873 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 77 | 0.100 |
Why?
|
| Acute-Phase Reaction | 1 | 2011 | 91 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 892 | 0.100 |
Why?
|
| Disease Progression | 9 | 2022 | 13286 | 0.100 |
Why?
|
| Survival Rate | 7 | 2021 | 12788 | 0.100 |
Why?
|
| Follow-Up Studies | 10 | 2023 | 39052 | 0.100 |
Why?
|
| Acid Phosphatase | 2 | 2007 | 143 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 4851 | 0.100 |
Why?
|
| Drug Therapy, Combination | 4 | 2014 | 6489 | 0.100 |
Why?
|
| Retinoblastoma Protein | 2 | 2009 | 705 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2018 | 1369 | 0.100 |
Why?
|
| Pyridines | 2 | 2016 | 2825 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2013 | 428 | 0.090 |
Why?
|
| Rhabdomyosarcoma | 1 | 1993 | 382 | 0.090 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 277 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2022 | 2016 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 1276 | 0.090 |
Why?
|
| Mutation, Missense | 2 | 2018 | 2566 | 0.090 |
Why?
|
| POEMS Syndrome | 1 | 2010 | 19 | 0.090 |
Why?
|
| Cell Movement | 5 | 2016 | 5218 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2012 | 180 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1031 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 3 | 2013 | 1525 | 0.090 |
Why?
|
| Activin Receptors, Type II | 1 | 2010 | 127 | 0.090 |
Why?
|
| Life Style | 1 | 2021 | 3835 | 0.090 |
Why?
|
| Disease Models, Animal | 6 | 2015 | 18034 | 0.090 |
Why?
|
| Cells, Cultured | 9 | 2013 | 19233 | 0.090 |
Why?
|
| Smad2 Protein | 1 | 2010 | 156 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 934 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 1714 | 0.090 |
Why?
|
| Lymphocyte Activation | 5 | 2018 | 5524 | 0.090 |
Why?
|
| Vincristine | 5 | 2001 | 1039 | 0.090 |
Why?
|
| Interferon-alpha | 4 | 1998 | 895 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2009 | 55 | 0.090 |
Why?
|
| Interleukin-17 | 1 | 2015 | 901 | 0.090 |
Why?
|
| Maytansine | 1 | 2009 | 80 | 0.080 |
Why?
|
| Central Nervous System | 1 | 1996 | 1357 | 0.080 |
Why?
|
| Cerulenin | 1 | 2008 | 7 | 0.080 |
Why?
|
| Receptors, CCR5 | 1 | 2011 | 498 | 0.080 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2010 | 279 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2008 | 434 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1799 | 0.080 |
Why?
|
| Quinazolinones | 1 | 2010 | 221 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2016 | 2126 | 0.080 |
Why?
|
| Interferons | 4 | 2001 | 706 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 1660 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2018 | 1860 | 0.080 |
Why?
|
| Bone Density | 2 | 2012 | 3468 | 0.080 |
Why?
|
| Sacrum | 1 | 2010 | 288 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2013 | 810 | 0.080 |
Why?
|
| Azepines | 1 | 2010 | 334 | 0.080 |
Why?
|
| Caregivers | 2 | 2022 | 2095 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 2850 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2009 | 624 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2023 | 841 | 0.080 |
Why?
|
| Drug Approval | 1 | 2014 | 742 | 0.080 |
Why?
|
| Metformin | 1 | 2014 | 836 | 0.080 |
Why?
|
| Cell Fusion | 2 | 2007 | 297 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2327 | 0.080 |
Why?
|
| Fever | 2 | 1996 | 1616 | 0.080 |
Why?
|
| Polymethyl Methacrylate | 1 | 2008 | 145 | 0.070 |
Why?
|
| DNA, Neoplasm | 3 | 2007 | 1758 | 0.070 |
Why?
|
| Hydroquinones | 1 | 2007 | 36 | 0.070 |
Why?
|
| Mandibular Diseases | 1 | 2008 | 119 | 0.070 |
Why?
|
| Albumins | 1 | 2010 | 568 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1062 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 381 | 0.070 |
Why?
|
| Endothelial Cells | 3 | 2011 | 3486 | 0.070 |
Why?
|
| Risk Factors | 3 | 2023 | 72296 | 0.070 |
Why?
|
| Azo Compounds | 1 | 2007 | 113 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 4 | 2011 | 2638 | 0.070 |
Why?
|
| Authorship | 1 | 2010 | 271 | 0.070 |
Why?
|
| Killer Cells, Natural | 3 | 2010 | 2133 | 0.070 |
Why?
|
| Amyloid | 1 | 2012 | 795 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2006 | 1157 | 0.070 |
Why?
|
| Ulcer | 1 | 2008 | 209 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2006 | 3511 | 0.070 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 3464 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2007 | 140 | 0.070 |
Why?
|
| Femoral Fractures | 1 | 2010 | 376 | 0.070 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2007 | 190 | 0.070 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2006 | 83 | 0.070 |
Why?
|
| Ribonucleotide Reductases | 1 | 2006 | 77 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 1584 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2007 | 146 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2007 | 286 | 0.070 |
Why?
|
| Actins | 1 | 2014 | 2121 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2006 | 172 | 0.070 |
Why?
|
| Naphthalenes | 1 | 2006 | 194 | 0.070 |
Why?
|
| DNA-Binding Proteins | 5 | 2010 | 9647 | 0.070 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 135 | 0.070 |
Why?
|
| Isoenzymes | 2 | 2007 | 1728 | 0.070 |
Why?
|
| Flavoproteins | 1 | 2005 | 43 | 0.070 |
Why?
|
| IMP Dehydrogenase | 1 | 2005 | 34 | 0.070 |
Why?
|
| Adamantane | 1 | 2007 | 173 | 0.070 |
Why?
|
| Cyclophosphamide | 5 | 2001 | 2242 | 0.070 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 651 | 0.070 |
Why?
|
| Gingiva | 1 | 2008 | 388 | 0.070 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2006 | 104 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 1994 | 1401 | 0.070 |
Why?
|
| Immunity, Cellular | 3 | 2013 | 1607 | 0.070 |
Why?
|
| Azacitidine | 1 | 2007 | 347 | 0.070 |
Why?
|
| Cell Growth Processes | 4 | 2007 | 399 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 484 | 0.060 |
Why?
|
| Propylene Glycols | 1 | 2005 | 92 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2009 | 721 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 2917 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5388 | 0.060 |
Why?
|
| Mucin-1 | 2 | 2000 | 543 | 0.060 |
Why?
|
| Exercise | 1 | 2021 | 5615 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2018 | 2349 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2007 | 215 | 0.060 |
Why?
|
| Immunoblotting | 4 | 2014 | 1683 | 0.060 |
Why?
|
| Forecasting | 1 | 2014 | 2951 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2006 | 411 | 0.060 |
Why?
|
| Kidney Diseases | 2 | 2010 | 2148 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 544 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2020 | 9955 | 0.060 |
Why?
|
| Bone Regeneration | 1 | 2008 | 427 | 0.060 |
Why?
|
| Recombinant Proteins | 6 | 2007 | 6621 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 11366 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2016 | 1915 | 0.060 |
Why?
|
| Spiro Compounds | 1 | 2005 | 76 | 0.060 |
Why?
|
| Lignans | 1 | 2005 | 81 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2005 | 211 | 0.060 |
Why?
|
| DNA, Viral | 3 | 2000 | 2227 | 0.060 |
Why?
|
| HLA-DR Antigens | 2 | 2013 | 645 | 0.060 |
Why?
|
| Endodeoxyribonucleases | 1 | 2005 | 165 | 0.060 |
Why?
|
| Health Policy | 1 | 1996 | 2661 | 0.060 |
Why?
|
| Caspase 9 | 3 | 2011 | 188 | 0.060 |
Why?
|
| Registries | 1 | 2019 | 8091 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 6755 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2022 | 53290 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 4 | 2007 | 440 | 0.060 |
Why?
|
| Caspase 8 | 3 | 2011 | 195 | 0.060 |
Why?
|
| Disclosure | 1 | 2010 | 736 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2004 | 518 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2015 | 13035 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2265 | 0.060 |
Why?
|
| Drug Industry | 1 | 2010 | 746 | 0.060 |
Why?
|
| Glucocorticoids | 2 | 2006 | 2108 | 0.060 |
Why?
|
| Glioma | 1 | 2018 | 3401 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 3921 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2010 | 3309 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2005 | 294 | 0.060 |
Why?
|
| Mandible | 1 | 2008 | 740 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 4751 | 0.060 |
Why?
|
| Melanoma | 1 | 2021 | 5511 | 0.050 |
Why?
|
| Radiography | 2 | 2011 | 7023 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 4666 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2010 | 2938 | 0.050 |
Why?
|
| RNA, Small Interfering | 5 | 2011 | 3505 | 0.050 |
Why?
|
| Hematologic Diseases | 2 | 2021 | 498 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2006 | 4424 | 0.050 |
Why?
|
| Endothelial Growth Factors | 2 | 2003 | 694 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3611 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 1085 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2007 | 2007 | 0.050 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2013 | 685 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2011 | 692 | 0.050 |
Why?
|
| Caspase 3 | 3 | 2011 | 758 | 0.050 |
Why?
|
| Lymphokines | 2 | 2003 | 949 | 0.050 |
Why?
|
| Fatigue | 3 | 2022 | 1531 | 0.050 |
Why?
|
| Time Factors | 5 | 2018 | 40075 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8385 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 12961 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 12746 | 0.050 |
Why?
|
| Antioxidants | 1 | 2009 | 1659 | 0.050 |
Why?
|
| Trans-Activators | 3 | 2008 | 2926 | 0.050 |
Why?
|
| Immunotherapy, Active | 1 | 2000 | 60 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2006 | 329 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 2418 | 0.050 |
Why?
|
| Cytokine Receptor gp130 | 2 | 2016 | 66 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 2865 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 994 | 0.050 |
Why?
|
| Leukemia | 1 | 2008 | 1510 | 0.050 |
Why?
|
| Breast Neoplasms | 5 | 2012 | 20824 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 40559 | 0.050 |
Why?
|
| Methionine | 1 | 2022 | 590 | 0.050 |
Why?
|
| Antigens, Nuclear | 1 | 2000 | 192 | 0.050 |
Why?
|
| United States | 3 | 2018 | 69872 | 0.050 |
Why?
|
| Idarubicin | 1 | 1999 | 62 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 2000 | 80 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12262 | 0.040 |
Why?
|
| Verapamil | 2 | 1997 | 244 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 20130 | 0.040 |
Why?
|
| India | 2 | 1996 | 2197 | 0.040 |
Why?
|
| Jaw | 1 | 2019 | 96 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 1968 | 0.040 |
Why?
|
| Echocardiography | 1 | 2011 | 5099 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2006 | 7882 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1431 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3616 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 240 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2022 | 2618 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2010 | 1905 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2004 | 1284 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2000 | 473 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2000 | 623 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2007 | 2943 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2375 | 0.040 |
Why?
|
| Vertebroplasty | 1 | 2019 | 77 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 1622 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 847 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2006 | 772 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2005 | 1904 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 494 | 0.040 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2008 | 111 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17446 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 8861 | 0.040 |
Why?
|
| Myeloma Proteins | 1 | 2017 | 72 | 0.040 |
Why?
|
| I-kappa B Proteins | 2 | 2009 | 225 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 506 | 0.040 |
Why?
|
| Hodgkin Disease | 2 | 2002 | 1415 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 1996 | 7182 | 0.040 |
Why?
|
| Antigens, CD34 | 2 | 1996 | 659 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5223 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 2700 | 0.040 |
Why?
|
| Comorbidity | 1 | 2011 | 10388 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12356 | 0.040 |
Why?
|
| Autoantigens | 1 | 2000 | 892 | 0.030 |
Why?
|
| Spine | 1 | 2023 | 1144 | 0.030 |
Why?
|
| Valine | 1 | 2018 | 413 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2282 | 0.030 |
Why?
|
| Paraproteins | 1 | 1995 | 39 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 3480 | 0.030 |
Why?
|
| Troponin | 1 | 2019 | 524 | 0.030 |
Why?
|
| Viral Proteins | 2 | 2000 | 1900 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 1995 | 157 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2000 | 861 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2006 | 300 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 2 | 2008 | 317 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2023 | 2617 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 1677 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2017 | 374 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 1213 | 0.030 |
Why?
|
| Neuroectodermal Tumor, Melanotic | 1 | 1994 | 3 | 0.030 |
Why?
|
| Models, Biological | 1 | 2011 | 9584 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2014 | 250 | 0.030 |
Why?
|
| Methylprednisolone | 3 | 2001 | 387 | 0.030 |
Why?
|
| Daunorubicin | 1 | 1994 | 158 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 21833 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 684 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 571 | 0.030 |
Why?
|
| Maxillary Neoplasms | 1 | 1994 | 45 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 15160 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2014 | 140 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2016 | 401 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 35425 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2017 | 881 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2013 | 45 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 1793 | 0.030 |
Why?
|
| HIV Infections | 1 | 2019 | 16715 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 564 | 0.030 |
Why?
|
| Asparaginase | 1 | 1994 | 236 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 1707 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 2645 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2002 | 1352 | 0.030 |
Why?
|
| Heat-Shock Proteins | 2 | 2008 | 822 | 0.030 |
Why?
|
| Cytarabine | 1 | 1994 | 692 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 1678 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2000 | 2036 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2022 | 8319 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 11126 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2000 | 4026 | 0.030 |
Why?
|
| Glutamine | 1 | 2014 | 579 | 0.030 |
Why?
|
| Gene Expression | 3 | 2014 | 7798 | 0.030 |
Why?
|
| Diketopiperazines | 1 | 2011 | 20 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 973 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1771 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 428 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 610 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 25039 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2018 | 1348 | 0.020 |
Why?
|
| Mycoses | 1 | 1994 | 376 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 1872 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 2542 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 397 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 6171 | 0.020 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 2000 | 86 | 0.020 |
Why?
|
| Cell Separation | 1 | 2016 | 1751 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2018 | 1928 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 1988 | 0.020 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2009 | 33 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 1837 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 433 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 175 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1994 | 613 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 193 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2008 | 3390 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 693 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2018 | 21748 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2010 | 156 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2001 | 335 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2010 | 244 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2016 | 828 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2008 | 68 | 0.020 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2008 | 40 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 2012 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 1120 | 0.020 |
Why?
|
| Gingival Diseases | 1 | 2008 | 34 | 0.020 |
Why?
|
| Brachial Plexus | 1 | 2010 | 163 | 0.020 |
Why?
|
| Precipitating Factors | 1 | 2008 | 52 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 1868 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 708 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 2007 | 191 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 2 | 2006 | 1351 | 0.020 |
Why?
|
| Ascites | 1 | 2010 | 344 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2008 | 148 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 129 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4185 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2001 | 647 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2007 | 123 | 0.020 |
Why?
|
| Mitochondria | 2 | 2014 | 3514 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 4561 | 0.020 |
Why?
|
| Flavonoids | 2 | 2001 | 443 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 1537 | 0.020 |
Why?
|
| Heart Failure | 1 | 2011 | 10895 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 2010 | 354 | 0.020 |
Why?
|
| Genes, fos | 1 | 2007 | 183 | 0.020 |
Why?
|
| Cathepsins | 1 | 2008 | 241 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2007 | 193 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 2428 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2019 | 5006 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2008 | 222 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 647 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2022 | 4245 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 5077 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4805 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2007 | 189 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2006 | 65 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3207 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 215 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 607 | 0.020 |
Why?
|
| Homeostasis | 1 | 2017 | 3339 | 0.020 |
Why?
|
| Lymphocyte Count | 2 | 2001 | 793 | 0.020 |
Why?
|
| Benzoquinones | 1 | 2006 | 201 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 1997 | 403 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 1533 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 593 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2006 | 47 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2010 | 890 | 0.020 |
Why?
|
| Transfection | 2 | 2007 | 5895 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 4262 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 201 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2005 | 55 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2006 | 114 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 1617 | 0.020 |
Why?
|
| Somatomedins | 1 | 2006 | 192 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2009 | 959 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 2598 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 62 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 4459 | 0.020 |
Why?
|
| Stem Cells | 2 | 2010 | 3567 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2216 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2076 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2006 | 278 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2005 | 326 | 0.020 |
Why?
|
| G2 Phase | 1 | 2005 | 139 | 0.020 |
Why?
|
| Lactams, Macrocyclic | 1 | 2006 | 320 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 13104 | 0.020 |
Why?
|
| Angiopoietin-2 | 1 | 2006 | 172 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1420 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12244 | 0.020 |
Why?
|
| Adolescent | 3 | 2020 | 85779 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2004 | 158 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5321 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 295 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 220 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2005 | 624 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2008 | 1899 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 644 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2006 | 982 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 2004 | 324 | 0.010 |
Why?
|
| Growth Substances | 1 | 2006 | 784 | 0.010 |
Why?
|
| Incidence | 2 | 2015 | 20952 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 898 | 0.010 |
Why?
|
| Sphingosine | 1 | 2005 | 307 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2009 | 1423 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 573 | 0.010 |
Why?
|
| Young Adult | 2 | 2020 | 56429 | 0.010 |
Why?
|
| Depression | 1 | 2022 | 7759 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 10637 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2005 | 381 | 0.010 |
Why?
|
| Risk | 1 | 2015 | 9688 | 0.010 |
Why?
|
| Physician's Role | 1 | 2010 | 943 | 0.010 |
Why?
|
| Immune System | 1 | 2008 | 806 | 0.010 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2008 | 496 | 0.010 |
Why?
|
| Cell Death | 1 | 2008 | 1707 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1996 | 41005 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2005 | 1137 | 0.010 |
Why?
|
| Genotype | 1 | 2016 | 12952 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 2727 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15535 | 0.010 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2001 | 48 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1379 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2013 | 1947 | 0.010 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 1 | 2000 | 45 | 0.010 |
Why?
|
| DNA | 2 | 2005 | 7294 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 1988 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 203 | 0.010 |
Why?
|
| Necrosis | 1 | 2005 | 1643 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 277 | 0.010 |
Why?
|
| Models, Animal | 1 | 2007 | 2173 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2000 | 122 | 0.010 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2000 | 117 | 0.010 |
Why?
|
| STAT2 Transcription Factor | 1 | 2000 | 27 | 0.010 |
Why?
|
| Cell-Free System | 1 | 2000 | 344 | 0.010 |
Why?
|
| Janus Kinase 1 | 1 | 2000 | 104 | 0.010 |
Why?
|
| Thrombocytopenia | 2 | 1999 | 1178 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2001 | 261 | 0.010 |
Why?
|
| src Homology Domains | 1 | 2000 | 364 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 903 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2000 | 234 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2000 | 258 | 0.010 |
Why?
|
| Pain | 2 | 2010 | 4988 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 3130 | 0.010 |
Why?
|
| G1 Phase | 1 | 2000 | 415 | 0.010 |
Why?
|
| Cyclin D | 1 | 1999 | 72 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2000 | 743 | 0.010 |
Why?
|
| Hybridomas | 1 | 2000 | 452 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1999 | 258 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2000 | 320 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 2027 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2000 | 225 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1999 | 162 | 0.010 |
Why?
|
| RNA Interference | 1 | 2007 | 2890 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2000 | 698 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 1101 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2000 | 489 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 1801 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2002 | 1035 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2000 | 758 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1999 | 320 | 0.010 |
Why?
|
| Busulfan | 1 | 1998 | 263 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2003 | 1539 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 755 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 3646 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 23336 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2000 | 769 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 850 | 0.010 |
Why?
|
| Child | 2 | 1996 | 77709 | 0.010 |
Why?
|
| Filgrastim | 1 | 1996 | 133 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 131 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9735 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2000 | 528 | 0.010 |
Why?
|
| Cyclins | 1 | 1999 | 603 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2219 | 0.010 |
Why?
|
| Convalescence | 1 | 1996 | 105 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2001 | 1227 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 370 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1999 | 995 | 0.010 |
Why?
|
| Graft Survival | 2 | 1996 | 3737 | 0.010 |
Why?
|
| Cytapheresis | 1 | 1995 | 8 | 0.010 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1996 | 302 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 1547 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 1995 | 109 | 0.010 |
Why?
|
| Tyrosine | 1 | 2000 | 1462 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 1641 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1995 | 380 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 1919 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1996 | 231 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1995 | 211 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1998 | 607 | 0.010 |
Why?
|
| Phenotype | 2 | 2003 | 16367 | 0.010 |
Why?
|
| Epitopes | 1 | 2000 | 2571 | 0.010 |
Why?
|
| DNA Replication | 1 | 2000 | 1399 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2002 | 2901 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 1996 | 314 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1783 | 0.010 |
Why?
|
| Temperature | 1 | 2000 | 2204 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 4982 | 0.010 |
Why?
|
| Kinetics | 1 | 2000 | 6476 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 13882 | 0.010 |
Why?
|
| Plasma | 1 | 1995 | 575 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1995 | 1588 | 0.010 |
Why?
|
| Drug Utilization | 1 | 1996 | 1183 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1995 | 689 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1996 | 985 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 6100 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 3771 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1996 | 2073 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1997 | 2616 | 0.000 |
Why?
|
| Protein Binding | 1 | 1999 | 9384 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1995 | 2455 | 0.000 |
Why?
|
| Genetic Variation | 1 | 2000 | 6542 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1997 | 3531 | 0.000 |
Why?
|
| Length of Stay | 1 | 1996 | 6311 | 0.000 |
Why?
|
| Age Factors | 1 | 1997 | 18373 | 0.000 |
Why?
|
| Infant | 1 | 1994 | 35134 | 0.000 |
Why?
|